Adverse events in IBD: to stop or continue immune suppressant and biologic treatment - Wikidata - awgldk - TriplyDB

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

http://www.wikidata.org/entity/Q34073191

about

Pharmacologic therapy for inflammatory bowel disease refractory to steroids Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn's Colitis The role and advances of immunomodulator therapy for inflammatory bowel disease.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.The safety of vedolizumab for ulcerative colitis and Crohn's disease.Methionine restriction on oxidative stress and immune response in dss-induced colitis mice.Therapeutic efficacy and mechanism of Zhenrenyangzang decoction in rats with experimental ulcerative colitis Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.The Inflammatory Bowel Disease Specialty Medical Home: A New Model of Patient-centered Care.Pyrrolidine Dithiocarbamate Inhibits NF-KappaB Activation and Upregulates the Expression of Gpx1, Gpx4, Occludin, and ZO-1 in DSS-Induced Colitis.Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.Complementary and Alternative Medicine.

P2860

Q26796415-DBEFE4EB-530F-4B42-8DB5-2AABC0F1BB61 Q37249964-85F29CF1-4A96-4044-8040-55606FC45899 Q38237701-6E97C207-CF47-49A2-A606-6DBD57E680EE Q38563075-BAA7FFBA-E26F-4B5A-A284-6C217ACA2EA1 Q38582914-181A8E55-7411-47E8-91D2-AB0874E45BDE Q38611360-21B2A8A7-AF36-4C83-8169-559AC12C7A0B Q38751610-7B9484F5-1007-406D-BAF4-F593918AE476 Q38812688-E3464578-DBC1-4490-A432-46508BC8D9FC Q39120032-8D9F7CDE-DA75-4CA0-8195-B33FFE027C72 Q39250092-52FD7BCC-8D5B-4CE9-8241-BC73491B8692 Q39985219-DD129905-8566-4043-BAD3-139DD34931B5 Q41280134-887CBCD8-A9F0-40A9-B37C-A9B3B691EAB4 Q41827848-15FB7055-CBBF-4290-BFB7-4E18C633EA15 Q41846031-62D91A66-60E9-4A13-8687-C2EAA638BC01 Q41921482-3B768F7D-7181-4FF4-BB76-0F3DD5BEC423 Q48056630-FF65F5E7-530B-4F10-B7A7-EB0C888E9AD8 Q51333250-590EFA71-D1B6-4E04-ACF1-9AECEBAAC735 Q52618987-A79D2106-BEBC-4294-928E-E7AD92DB655C Q53968303-AAEF1C54-E007-4CD4-9887-5AF4C07341B8

P2860

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

http://www.wikidata.org/entity/Q34073191

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@ast

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@en

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@nl

type

label

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@ast

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@en

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@nl

prefLabel

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@ast

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@en

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@nl

P1433

Q34073191-94E08F93-83AD-4B9C-9D47-1242DD49D0D9

P1476

Q34073191-3B2FFD01-F832-429C-B2D0-6C35CB335D2C

P2093

Q34073191-6B7BA6DF-E9E5-456E-822E-E67D5BCB3ECB

Q34073191-A11D68E4-EE15-4580-B194-47AA1F9097C0

P2860

Q34073191-00C10660-D4F1-42EC-8BAF-91771E069D52

Q34073191-026BD4FF-3C02-4F68-BAEF-212607BD1309

Q34073191-03A329A9-166B-4675-9BBD-740317A91A6E

Q34073191-041D0F8A-65DC-4E6C-86B7-BFB4B4EC13F7

Q34073191-08B01BA7-AEB2-4F89-B090-4404BF8A3819

Q34073191-091A6851-A4B1-466B-A29A-5B002979D580

Q34073191-092F01EC-871F-466E-B799-72EB291361FD

Q34073191-09889868-3568-4C9F-9D7F-A320F2E6A86A

Q34073191-09B4B571-8B34-44AD-862B-2E116F90AB27

Q34073191-0B8F0887-02E2-439D-B625-06DA8832A51C

P304

Q34073191-56BFBF1C-1568-46DB-BD6B-BDC04F4A5E9B

P31

Q34073191-BCF84381-45BA-479C-AEA6-1AA49582FEF2

P356

Q34073191-FDBE851E-44E3-45D0-BC26-E6593970215C

P433

Q34073191-52043D9C-B62D-4795-99C8-CF56FB99C961

P478

Q34073191-790EC53F-B3B1-4ADF-B472-B0A11866ECC5

P577

Q34073191-2D597A49-E0E4-4CDC-B6AB-71F68BEE2A08

P5875

Q34073191-38027F4D-0DFE-4C67-8DD7-D0A05EBE5A16

P698

Q34073191-A836E415-0ADF-4AED-8DF8-AD917A409F54

P932

Q34073191-0B2D9859-E38B-4D9A-A148-D77364D55494

P356

17474124.2014.881715

P1433

Expert Review of Gastroenterology & Hepatology

P1476

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

@en

P2093

Leon P McLean

http://www.w3.org/2001/XMLSchema#string

Raymond K Cross

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

Aminosalicylates for induction of remission or response in Crohn's disease

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Methotrexate for induction of remission in refractory Crohn's disease

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

P304

223-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474124.2014.881715

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260064228

http://www.w3.org/2001/XMLSchema#string

P698

24490595

http://www.w3.org/2001/XMLSchema#string

P932

4140086

http://www.w3.org/2001/XMLSchema#string